​​​​​

  • Image of microscope

    Is a cure for Tuberculosis possible?

    Researchers at Baylor Scott & White Research Institute have made a groundbreaking discovery in the treatment of TB.

  • Image of tumeric powder

    A study of BCM-95 turmeric extract reveals new mechanisms in anti-chemoresistance

    A recent clinical study at Baylor Scott & White Health showed BCM-95 may help overcome some cases of chemotherapy resistance during pancreatic cancer treatment.

  • Image of veins in legs

    Isolated lower extremity vasculitis leads to progressive critical limb ischemia

    How did we treat a patient with isolated bilateral limb claudication who rapidly progressed to critical limb ischemia and required urgent surgical intervention after steroid therapy?

Our people are at the forefront of health care

Why Baylor Scott & White Health

We’ve created a transformative model for the health care industry that eliminates waste, improves coordination of care and helps us better manage chronic disease.

Continuing Medical Education (CME)

As an accredited provider for the Accreditation Council for Continuing Medical Education (ACCME), we offer conferences—both live and online—at locations across our organization and the Southwest.

Our Departments

Our extensive network of 48 hospitals and more than 900 patient care sites – including specialized centers, institutes and regional clinics – offers your patients a full range of medical expertise.

Innovation with a commitment to every patient

Image of plaque in artery

Turning guidelines into outcomes

Are current ACC/AHA guidelines too long to be effective? We discuss whether future guidelines should only include recommendations based on high-quality data that is limited to a single page that physicians can reference easier.

Image of teddy bear

Pediatric CME opportunity

Sign up for an upcoming conference to help primary care providers recognize and evaluate specific pediatric subspecialty disorders seen frequently in primary care office settings.

Illustration of insulin

Type 1 diabetes clinical trial

We currently have a phase 3 study to compare LY2963016 and Lantus with mealtime insulin lispro in adult patients with type 1 diabetes mellitus with a 28-week extension and 4-week post-treatment follow-up.